Home
About
Services
Portfolio
Contact
More
Patient-reported outcomes in chronic hepatitis delta: an exploratory analysis of the phase III MYR301 trial of bulevirtide
More time spent with clear skin and no itch with upadacitinib versus dupilumab for atopic dermatitis
Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
Assignment of the gene for acetylcholinesterase to distal mouse chromosome 5
Molecular cloning of mouse acetylcholinesterase: tissue distribution of alternatively spliced mRNA species
Preventive and acute treatment of migraine: new and emerging targeted therapies
Oral agent increases survival in advanced HER2-positive breast cancer
Targeted agent offers treatment for sickle cell disease
REVIEW ARTICLES
Management of patients with advanced gastrointestinal stromal tumor: emphasis on fourth-line treatment with ripretinib
The benefit of telemedicine in obesity care
ABSTRACTS
Tissue frataxin increases after administration of CTI-1601, a frataxin replacement therapy in development for the treatment of Friedreich's ataxia (#9 at link)
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of CTI-1601 (#10 at link)
Achieving incrementally greater skin improvement thresholds with upadacitinib versus dupilumab in moderate-to-severe atopic dermatitis (AD): Heads Up study results
EDITORIAL
The future of prenatal molecular diagnostics: impact of the changing patent landscape
NEWSLETTER ARTICLE
What’s your niche: exploring the medical writing habitat
